GlaxoSmithKline, Pfizer, Shionogi deal
ViiV Healthcare Ltd. acquired exclusive, worldwide rights to develop and commercialize a portfolio of HIV integrase inhibitors from Shionogi-ViiV Healthcare LLC, a JV between ViiV and Shionogi. The portfolio includes dolutegravir ( S/GSK1349572), for which worldwide regulatory submissions to treat HIV-1 infection are slated by year end; ' 572-Trii, a triple combination of dolutegravir plus the marketed nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine in Phase III testing; and S/GSK1265744, which is in Phase IIb testing. Shionogi will own a 10% stake in ViiV and is eligible for dividends, plus royalties in the "high teens" on sales of the portfolio assets. For an undisclosed period post-launch, the royalty applies to sales above minimum thresholds. The royalty applies to all sales after that period. Shionogi will also gain a seat on ViiV's board. ...